Immutep Announces Positive Interim Results In Phase I/II Chemoimmunotherapy Trial In

[News]

Immutep S.A. announced today interim results from its ongoing Phase I/II chemoimmunotherapy clinical trial in metastatic breast carcinoma. ImmuFact IMP321 was administered the day after weekly paclitaxel for six months. The interim results show a clinical response rate of 50 per cent compared to 25 per cent with paclitaxel alone. In addition, a robust immune response was observed in clinically-responding patients.

More... (http://www.medicalnewstoday.com/articles/134393.php)